MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-27-2026
Establishment Labs Holdings Net Income 2011-2026 | ESTA
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Establishment Labs Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -51.1 M | -84.6 M | -78.5 M | -75.2 M | -41.1 M | -38.1 M | -38.2 M | -21.1 M | -34.9 M | -22.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21.1 M | -84.6 M | -48.5 M |
Quarterly Net Income Establishment Labs Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.1 M | -16.6 M | -20.7 M | - | -16.7 M | -17.2 M | -16.2 M | - | -29.3 M | -16.7 M | -11.9 M | - | -18.6 M | -37.1 M | -5.93 M | - | -14.7 M | -5.32 M | -6.95 M | - | -4.24 M | -10.5 M | -17.8 M | - | -12.8 M | -9.04 M | -10.8 M | - | 1.31 M | -5.36 M | -6.53 M | - | -10.7 M | -12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.31 M | -37.1 M | -13.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Delcath Systems
DCTH
|
2.7 M | $ 11.42 | 3.63 % | $ 409 M | USA |
 |
Second Sight Medical Products
EYES
|
-26.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
7.54 M | $ 26.23 | 2.62 % | $ 222 M | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | $ 3.45 | 1.71 % | $ 129 M |  France |
 |
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | USA |
 |
Helius Medical Technologies
HSDT
|
-8.85 M | $ 2.14 | -0.93 % | $ 1.3 M | USA |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
Inspire Medical Systems
INSP
|
145 M | $ 45.59 | -16.87 % | $ 1.34 B | USA |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 11.03 | -1.34 % | $ 312 M | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.62 | 0.47 % | $ 38.6 M | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
LivaNova PLC
LIVN
|
-242 M | $ 56.96 | -3.57 % | $ 3.11 B |  Britain |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 1.05 | -3.69 % | $ 17.8 M | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 16.18 | 2.5 % | $ 380 M | USA |
 |
Insulet Corporation
PODD
|
247 M | $ 169.04 | -1.37 % | $ 11.9 B | USA |
 |
Butterfly Network
BFLY
|
-72.5 M | $ 5.0 | 2.99 % | $ 1.06 B | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 2.39 | -1.24 % | $ 6.63 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
538 M | $ 91.11 | 0.56 % | $ 12.3 B | USA |
 |
NanoVibronix
NAOV
|
-18.2 M | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
47.1 M | $ 36.09 | 0.59 % | $ 1.12 B | USA |
 |
TransMedics Group
TMDX
|
190 M | $ 95.4 | -1.73 % | $ 3.24 B | USA |
 |
Tandem Diabetes Care
TNDM
|
-589 K | $ 19.18 | -3.47 % | $ 1.3 B | USA |
 |
Integer Holdings Corporation
ITGR
|
103 M | $ 86.99 | 3.62 % | $ 3.02 B | USA |
 |
Stryker Corporation
SYK
|
849 M | $ 295.85 | 1.71 % | $ 113 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 83.06 | -0.32 % | $ 48.6 B | USA |
 |
LENSAR
LNSR
|
-34.3 M | $ 5.51 | -0.9 % | $ 65.9 M | USA |
 |
Pulmonx Corporation
LUNG
|
-54 M | $ 1.29 | -3.38 % | $ 52.5 M | USA |
 |
MiMedx Group
MDXG
|
48.6 M | $ 3.7 | 2.49 % | $ 547 M | USA |
 |
Myomo
MYO
|
-15.6 M | $ 0.87 | 0.15 % | $ 36.4 M | USA |